Veracyte Announces New Clinical Utility Data Suggesting Envisia Genomic Classifier Enables as Confident a Diagnosis in IPF as Surgical Pathology
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: Business Wire
– Interim CATALYST Study Findings Presented at PFF Summit – SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced that new data for the Envisia™ Genomic Classifier were presented today and demonstrate that the test – in real-world clinical scenarios – can enable diagnosis of idiopathic pulmonary fibrosis (IPF) by a central multidisciplinary team (MDT), without the need for surgery. The findings are important because IPF is often challenging to distinguish from other interstitial lung diseases (ILDs) without invasive, costly and risky surgery. The new data were shared during the Pulmonary Fibrosis Foundation’s biannual PFF Summit, being held November 9-11 in Nashville, Tenn. In the interim report from the CATALYST clinical utility study, researchers found that two central MDTs – each comprised of a pulmonologist, radiologist and pathologist – diagnosed patients wit
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024Business Wire
- New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance [Yahoo! Finance]Yahoo! Finance
- New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceBusiness Wire
- CareDx appoints John Hanna as president and CEO [Seeking Alpha]Seeking Alpha
- Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 [Yahoo! Finance]Yahoo! Finance
VCYT
Earnings
- 2/22/24 - Miss
VCYT
Sec Filings
- 4/17/24 - Form 8-K/A
- 4/2/24 - Form 4
- 4/1/24 - Form 144
- VCYT's page on the SEC website